Document Classification

Section Type: RESULTS

Text: After 24 weeks, least-square mean changes from baseline in HbA (1c) in patients receiving taspoglutide 10 mg [-8 mmol/mol (se 1)] [-0. 77 % (se 0. 05)] or taspoglutide 20 mg [-11 mmol/mol (se 1)] [-0. 98 % (se 0. 05)] were non-inferior to insulin glargine [-9 mmol/mol (se 1)] [-0. 84 % (se 0. 05)] ; treatment difference of 0. 07 % (95 % CI -0. 06 to 0. 21) and -0. 14 % (95 % CI -0. 28 to -0. 01), for taspoglutide 10 and 20 mg, respectively, vs. insulin glargine.